Dr. Reddy?s (NYSE:RDY) and Zydus partner on breast cancer drug

Dr. Reddy’s Laboratories (NYSE:RDY) and Zydus Lifesciences have entered into a licensing agreement to co-market a Pertuzumab biosimilar for HER2-positive breast cancer in India.

Under the agreement, Dr. Reddy’s will receive semi-exclusive rights to co-market the biosimilar alongside Zydus, which will market the product under the brand name Sigrima™, while Dr. Reddy’s will do so under the brand name Womab®.

In addition to receiving an upfront licensing income, Zydus is also eligible for milestone payments based on the achievement of pre-defined targets.